191 related articles for article (PubMed ID: 38054381)
21. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group.
Sotlar K; George TI; Kluin P; Reiter A; Schwaab J; Panse J; Brockow K; Hartmann K; Sperr WR; Kristensen T; Nedoszytko B; Carter M; Bonadonna P; Lyons JJ; Kluin-Nelemans HC; Hermine O; Akin C; Broesby-Olsen S; Hoermann G; Triggiani M; Butterfield JH; Jawhar M; Gotlib J; Metcalfe DD; Orfao A; Arock M; Valent P; Horny HP
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1986-1998.e2. PubMed ID: 35724949
[TBL] [Abstract][Full Text] [Related]
22. Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
Baird JH; Gotlib J
Curr Hematol Malig Rep; 2018 Oct; 13(5):407-416. PubMed ID: 30155614
[TBL] [Abstract][Full Text] [Related]
23. Novel approaches to treating advanced systemic mastocytosis.
Gilreath JA; Tchertanov L; Deininger MW
Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
[TBL] [Abstract][Full Text] [Related]
24. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
[TBL] [Abstract][Full Text] [Related]
25. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.
Jawhar M; Schwaab J; Horny HP; Sotlar K; Naumann N; Fabarius A; Valent P; Cross NC; Hofmann WK; Metzgeroth G; Reiter A
Eur J Clin Invest; 2016 May; 46(5):392-7. PubMed ID: 26914980
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
DeAngelo DJ; George TI; Linder A; Langford C; Perkins C; Ma J; Westervelt P; Merker JD; Berube C; Coutre S; Liedtke M; Medeiros B; Sternberg D; Dutreix C; Ruffie PA; Corless C; Graubert TJ; Gotlib J
Leukemia; 2018 Feb; 32(2):470-478. PubMed ID: 28744009
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee.
McLornan DP; Czerw T; Damaj G; Ethell M; Gurnari C; Hernández-Boluda JC; Polverelli N; Schwaab J; Sockel K; Raffaella G; Onida F; Sánchez-Ortega I; Battipaglia G; Elena C; Gotlib J; Reiter A; Rossignol J; Ustun C; Valent P; Yakoub-Agha I; Radia DH
Leukemia; 2024 Apr; 38(4):699-711. PubMed ID: 38472477
[TBL] [Abstract][Full Text] [Related]
29. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.
Valent P; Akin C; Arock M; Gleixner KV; Greinix H; Hermine O; Horny HP; Ivanov D; Orfao A; Rabitsch W; Reiter A; Schulenburg A; Sotlar K; Sperr WR; Ustun C
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894806
[TBL] [Abstract][Full Text] [Related]
30. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
Reiter A; George TI; Gotlib J
Blood; 2020 Apr; 135(16):1365-1376. PubMed ID: 32106312
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.
Valent P
Hematology Am Soc Hematol Educ Program; 2015; 2015():98-105. PubMed ID: 26637707
[TBL] [Abstract][Full Text] [Related]
32. Systemic Mastocytosis: Advances in Diagnosis and Current Management.
Pullarkat ST; Wu W; Pullarkat V
Cancer Treat Res; 2021; 181():167-178. PubMed ID: 34626361
[TBL] [Abstract][Full Text] [Related]
33. Systemic mastocytosis: 2023 update on diagnosis and management in adults.
Costa A; Scalzulli E; Carmosino I; Capriata M; Ielo C; Masucci C; Passucci M; Martelli M; Breccia M
Expert Opin Emerg Drugs; 2023 Dec; 28(3):153-165. PubMed ID: 37256917
[TBL] [Abstract][Full Text] [Related]
34. Mastocytosis and related entities: a practical roadmap.
Beyens M; Elst J; van der Poorten ML; Van Gasse A; Toscano A; Verlinden A; Vermeulen K; Maes MB; Oude Elberink JNGH; Ebo D; Sabato V
Acta Clin Belg; 2023 Aug; 78(4):325-335. PubMed ID: 36259506
[TBL] [Abstract][Full Text] [Related]
35. Midostaurin: First Global Approval.
Kim ES
Drugs; 2017 Jul; 77(11):1251-1259. PubMed ID: 28612232
[TBL] [Abstract][Full Text] [Related]
36. Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms.
Tashi T; Deininger MW
Immunol Allergy Clin North Am; 2023 Nov; 43(4):723-741. PubMed ID: 37758409
[TBL] [Abstract][Full Text] [Related]
37. Relevant updates in systemic mastocytosis.
Coltoff A; Mascarenhas J
Leuk Res; 2019 Jun; 81():10-18. PubMed ID: 30978435
[TBL] [Abstract][Full Text] [Related]
38. Update on diagnostic approaches and therapeutic strategies in systemic mastocytosis.
Radia DH; Moonim MT
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101380. PubMed ID: 36333068
[TBL] [Abstract][Full Text] [Related]
39. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.
Kluin-Nelemans HC; Jawhar M; Reiter A; van Anrooij B; Gotlib J; Hartmann K; Illerhaus A; Oude Elberink HNG; Gorska A; Niedoszytko M; Lange M; Scaffidi L; Zanotti R; Bonadonna P; Perkins C; Elena C; Malcovati L; Shoumariyeh K; von Bubnoff N; Müller S; Triggiani M; Parente R; Schwaab J; Kundi M; Fortina AB; Caroppo F; Brockow K; Zink A; Fuchs D; Angelova-Fischer I; Yavuz AS; Doubek M; Mattsson M; Hagglund H; Panse J; Simonowski A; Sabato V; Schug T; Jentzsch M; Breynaert C; Várkonyi J; Kennedy V; Hermine O; Rossignol J; Arock M; Valent P; Sperr WR
Theranostics; 2021; 11(1):292-303. PubMed ID: 33391475
[TBL] [Abstract][Full Text] [Related]
40. Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis.
Lübke J; Schwaab J; Naumann N; Horny HP; Weiß C; Metzgeroth G; Kreil S; Cross NCP; Sotlar K; Fabarius A; Hofmann WK; Valent P; Gotlib J; Jawhar M; Reiter A
J Clin Oncol; 2022 Jun; 40(16):1783-1794. PubMed ID: 35235417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
